队列概况:英国的放射治疗数据集 (RTDS)
Sabrina Sandhu1, Michael Sharpe2, Úna Findlay2,3
1National Disease Registration Service (NDRS), NHS England, Leeds, UK sabrinasandhu@nhs.net.
BMJ open
|June 20, 2023
概括
放射治疗数据集 (RTDS) 收集NHS放射治疗的重要数据,用于服务规划和研究. 将RTDS与癌症登记和其他数据集联系起来,可以增强患者途径分析和临床实践见解.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 数据科学数据科学数据科学
背景情况:
- 放射治疗数据集 (RTDS) 要求每月从英格兰NHS资助的放射治疗提供者收集数据.
- 数据收集从2009年4月开始,国家疾病登记服务 (NDRS) 从2016年4月开始管理数据.
- 该数据集包括原发性疾病,治疗方式,意图,剂量和预约细节,从与癌症登记数据的联系中受益.
研究的目的:
- 为NHS资助的服务建立一个一致和可比的放射治疗数据库.
- 为服务规划,调试,临床实践和研究产生情报.
- 支持流行病学研究,监测临床实践,并协助临床试验设计.
主要方法:
- 在英格兰,放射治疗提供者必须每月提交数据.
- 与英国国家癌症登记,全身抗癌疗法 (SACT) 和医院病例统计 (HES) 数据集的数据链接.
- 持续收集数据并定期更新,以获取详细的放射治疗计划和输送信息.
主要成果:
- RTDS已与国家癌症和治疗数据集联系在一起,使得全面的患者途径分析成为可能.
- 研究比较了放射治疗结果,调查了死亡率因素,并评估了社会人口统计学治疗变异.
- 评估了COVID-19大流行对放射治疗服务的影响.
结论:
- 该RTDS是癌症流行病学研究的宝贵资源,识别治疗机会不平等.
- 它为服务规划,临床实践监测和研究提供了关键的情报.
- 持续的数据收集和规范更新将进一步提高其用于放射治疗研究和服务改进的实用性.
更多相关视频
相关概念视频
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Radiation: Applications
1.2K
The average temperature of Earth is the subject of much current discussion. Earth is in radiative contact with both the Sun and dark space; it receives almost all its energy from the radiation of the Sun and reflects some of it into outer space. Dark space is very cold, about 3 K, so Earth radiates energy into it. For instance, heat transfer occurs from soil and grasses, the rate of which can be so rapid that frost can occur on clear summer evenings, even in warm latitudes.
The average...
The average...
1.2K
Biological Effects of Radiation
15.6K
All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...
15.6K
Comparing the Survival Analysis of Two or More Groups
228
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
228
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Hazard Ratio
166
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
166


